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Background: Although mouse brain-derived, inactivated Japanese encephalitis vaccines (JE-MBs) have been
successfully used for a long time, potential rare neurological complications have prompted the development of a
Vero cell culture-derived inactivated vaccine (JE-VC). In a phase III clinical study, we aimed to compare the safety
and immunogenicity of a JE-VC, KD-287 with a JE-MB, JEV-GCC, in children.
Methods: In this multicenter, double-blinded, randomized controlled trial, the study population consisted of 205
healthy Korean children aged 12–23 months. Each subject was subcutaneously vaccinated with either KD-287 or
JEV-GCC twice at an interval of 2 weeks and then vaccinated once 12 months after the second vaccination.
Neutralizing antibodies were measured by the plaque reduction neutralization test using the homologous and
heterologous, as a post hoc analysis, challenge virus strains.
Results: The three-dose regimen of KD-287 showed a comparable safety profile with JEV-GCC except higher
incidence of fever after the first dose (30.4% and 14.7%, respectively). Most of the fever was mild degree (61.3%
and 66.7%, respectively). KD-287 fulfilled the non-inferiority criteria for seroconversion rate (SCR) and geometric
mean titer (GMT) of the neutralizing antibody, which were the primary endpoints, at 4 weeks after the third
vaccination (95% CI: −1.00, 3.10 for the SCR difference and 10.8, 17.6 for the GMT ratio). The SCRs of KD-287 were
all 100% and the GMTs were higher in the KD-287 group than in the JEV-GCC group after the second vaccination
and before and after the third vaccination (GMT ratio: 5.59, 20.13, and 13.79, respectively, p < 0.001 in all). GMTs
were higher in the KD-287 group in the heterologous analysis also (GMT ratio: 4.05, 5.15, and 4.19, respectively,
p < 0.001 in all).
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Conclusions: This study suggests that the KD-287, a JE-VC is as safe as and may be more effective than the licensed
MB-derived vaccine. KD-287 could thus be useful as a second-generation vaccine and substitute for the current
JE-MB vaccine in Korean children.
Trial registration: ClinicalTrials.gov: NCT01150942
Keywords: Japanese encephalitis, Vaccine, Vero cells, Clinical trialBackground
Japanese encephalitis (JE) is the leading cause of severe
viral infection of the central nervous system, mostly in
Asian children. Japanese encephalitis viruses (JEVs) are
transmitted by bird-biting mosquitoes, especially mosqui-
toes from the culex genus. There is no specific antiviral
treatment for JE, and vaccination is the single most import-
ant control measure [1,2]. Mouse brain-derived, inactivated
JE vaccines (JE-MBs) are available and are internationally
accepted. Two strains of JEV, the Nakayama and the
Beijing-1 strains, are used for the production of JE-MBs.
Rare but serious hypersensitivity reactions and neurological
complications have been reported following immunization
with JE-MBs, potentially resulting from the presence of
gelatin and murine neural proteins in the vaccines [3].
In 2009, an inactivated, Vero cell-derived JE vaccine
(JE-VC; IXIARO®, Intercell Biomedical, Livingston, UK)
employing SA 14-14-2 strain, was licensed in Europe, the
United States, and Australia. This vaccine has a lower po-
tential risk of serious neurological adverse reactions be-
cause it does not contain impurities from mouse-brain-
derived proteins. Two other JE-VCs prepared using
Beijing-1 strain (JEBIK®V, Biken, Kagawa, Japan and
ENCEVAC®, Chemo-Sero-Therapeutic Research Institute
[Kaketsuken], Kumamoto, Japan) have been used in Japan
[4,5]; however, only JE-MBs (Green Cross vaccine, Green
Cross, Yongin, Korea and Boryung vaccine, Boryung
Pharmaceutical, Seoul, Korea) and a live-attenuated virus
vaccine (CD.JEVAX®, Chengdu Institute of Biological
Products, Sichuan, China) have been used to immunize
children in South Korea [6,7]. There is a need for a JE-VC
in South Korea to provide sufficient vaccine supply and
overcome vaccine safety issues.
Although JE vaccines are routinely used in children of
toddler age in endemic areas, previous studies that re-
ported the safety and immunogenicity of JE-VC compared
with JE-MB were mainly adult and early childhood stud-
ies [8-12]. Furthermore, in a previous study of ENCE-
VAC® in Japanese children [12], a JE-VC was compared
with a JE-MB prepared using a homologous JEV strain
(Beijing-1). In this phase III non-inferiority study, we
aimed to compare the safety and immunogenicity of a JE-
VC, KD-287 (ENCEVAC®, Beijing-1 strain) with those of a
licensed JE-MB, JEV-GCC (Green Cross vaccine,
Nakayama strain) in Korean children aged 12–23 months.Methods
Participants
In this multicenter, double-blind, centrally randomized
controlled trial, the study population consisted of healthy
Korean children aged 12–23 months. The exclusion cri-
teria consisted of impaired immunologic function; under-
lying chronic diseases; previous immunization for JEV;
any investigational or non-registered drug use (during the
study period), blood derivative use, immunosuppressant
use, other immune-modifying drug use, or other vaccine
administration within 4 weeks preceding the first dose of
the study vaccine; history of encephalitis, meningitis, or
other neurological disease; and a previous history of aller-
gic reaction to components of the study vaccines. The
study was performed in accordance with the principles
outlined in the Declaration of Helsinki. Written informed
consent was obtained from each parent or guardian after
the possible consequences of the studies had been fully ex-
plained. The study protocol was approved by the Institu-
tional Review Board of Seoul National University Hospital
and the Korean Food and Drug Administration, as well as
independent review board at each study site.
The intention-to-treat (ITT) population comprised all
participants who were randomized to a study group, and
the safety population comprised all participants receiving
at least one vaccination. The per-protocol (PP) popula-
tion for analysis of immunogenicity consisted of the par-
ticipants who met all eligibility criteria, had completed




The JE test vaccine (KD-287) is a purified, freeze-dried,
inactivated vaccine containing the JEV strain Beijing-1,
which was adapted to grow in Vero cells. One vaccine
dose contained 4 μg/0.5 mL of purified and inactivated
virus, and it did not contain preservatives (such as thi-
merosal). KD-287 contained lactose, sodium phosphate,
polysorbate, and glycine as stabilizers. Immediately prior
to inoculation, a vial of KD-287 was reconstituted with
0.7 mL of distilled water.
The JE control vaccine (JEV-GCC) is a purified, liquid,
inactivated vaccine containing the JEV strain Nakayama.
This vaccine was derived from mouse brain tissue, and
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sal as a preservative.Clinical study
The clinical study was conducted in accordance with the
Rules of Immunization Practice, the Vaccination Guide-
lines in South Korea, and Good Clinical Practice guide-
lines. A centralized and computerized procedure was
used to randomly assign participants. The vaccines were
prepared and injected at the study sites by staff members
who were not blinded to treatment assignments; the
participants and all other investigators and staff members
remained blinded to treatment assignments throughout
the trial. The vaccine volumes for children under
36 months of age were half of the volumes for children
who were at least 36 months old and were either 0.25 mL
for children randomized to KD-287 or 0.5 mL for children
randomized to JEV-GCC at enrollment. Each subject was
subcutaneously vaccinated in the deltoid area twice at an
interval of 2 weeks and then vaccinated once 12 months
after the second vaccination as the primary immunization
series, based on the recommended schedule for conven-
tional JE vaccines in South Korea. This trial is registered
as a clinical trial (clinicaltrials.gov: NCT01150942), proto-
col number KD287-BR-CT-301.Safety
The children were observed for 30 min after inoculation
of each dose by the investigators, and a parent/guardian
was required to complete a diary card from days 0 to 7 to
record daily signs and symptoms and daily temperature.
Adverse events (AEs) were actively surveyed, and the oc-
currence of solicited local reactions (e.g., erythema, pain/
tenderness, or swelling) and systemic symptoms (e.g.,
fever, crying, diarrhea, vomiting, somnolence, irritability,
or decreased appetite) was documented. Onset date, end
date, severity, action taken, outcome, and the investigator’s
assessment of the relationship to the vaccination were re-
corded. All serious AEs (SAEs) between day 0 of the first
vaccination and 6 months after the third vaccination were
reported actively by parents/guardians or passively at each
visit after the first vaccination during study period and the
telephone interviews which were done at day 7 after each
vaccination and 6 months after the third vaccination.
Investigators and parents/guardians used a standard
scale to grade solicited AEs during the observation period.
Fever was defined as mild if the body temperature was
37.5–38.4°C, moderate if 38.5–39.4°C, and severe if ≥39.5°C.
Other systemic symptoms were considered mild if they
did not interfere with normal daily activities, moderate if
they resulted in some interference with normal daily activ-
ities, and severe if they prevented subjects from engaging
in normal daily activities. Erythema and swelling at theinjection site were defined as mild if the diameter was
<10 mm, moderate if 10–29 mm, and severe if ≥30 mm.
Immunogenicity
For measurement of neutralizing antibody titers, serum
was obtained from each subject before the first and third
vaccination and 4 weeks after the second and third vac-
cination; the serum was stored at −80°C until the time
of measurement. Levels of neutralizing antibodies were
measured by the plaque reduction neutralization test
(PRNT), the standard method for evaluating immuno-
genicity in JE vaccine trials [13,14]. The neutralizing
antibody titer was expressed as a reciprocal of the dilu-
tion of serum that produced a 50% reduction of plaque
formation (PRNT50) relative to the plaque number of
the diluted challenge virus in the absence of antiserum.
As the study vaccines contained different JEV strains
(Beijing-1 in KD-287 and Nakayama in JEV-GCC), serum
samples of the two groups were individually tested with
the corresponding vaccine strain as a challenge virus in
each sample (homologous analysis). In addition, as a
post hoc analysis, we also tested all serum samples with
the opposite vaccine strain as a challenge virus (heterol-
ogous analysis) to avoid potential bias in favor of either
strain [15].
Seropositivity was defined as a PRNT50 titer of 1:10 or
greater; this cut-off was established in animal experi-
ments [13]. The serum samples were tested at a starting
dilution of 1:10, then 4-fold serial dilutions up to 1,280,
or higher when needed, and the negative samples were
assigned a value of 1:5 for calculation purposes. A correl-
ation of neutralizing antibody titer with protective efficacy
was shown in a phase III study in Thailand supporting the
licensing of an inactivated JE-MB (JE-VAX) in the United
States [16]. Seroconversion was defined as a change from
seronegative to seropositive or a 4-fold increase in the
neutralizing antibody titer for a seropositive subject before
vaccination.
Statistical analysis
The primary objective of the study was to show the non-
inferiority of the test vaccine compared with the licensed
control vaccine in terms of primary immunogenicity
endpoints, as the homologous response. The secondary
objective was to evaluate and compare the safety and
tolerability of the two vaccines. Primary endpoints were
seroconversion rate (SCR) and geometric mean titer
(GMT) at 4 weeks after the third vaccination, and the
secondary endpoints were the SCRs and GMTs at
4 weeks after the second vaccine dose and before the
third vaccine dose. Non-inferiority of the test vaccine
would be shown if the lower limit of the 95% confidence
interval (CI) for the seroconversion difference (i.e., test
vaccine minus licensed vaccine) was higher than −10%
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(i.e., test vaccine divided by licensed vaccine) was higher
than 0.5. Their 95% CIs were computed by transforming
the results to a logarithmic scale [14]. All immunogen-
icity data in the heterologous response were additionally
obtained in the post hoc analysis.
We calculated that 200 participants would be needed
to show non-inferiority of the SCR with a presumptive
drop-out rate of 25%, a two-sided 95% CI, and a power
of 80%, assuming a SCR of 95% in both groups. All im-
munogenicity assessments were performed on both the
PP (n = 188) and ITT (n = 205) populations. Because
there are no significant differences between the two pop-
ulations, the data of PP population are shown. The safety
of the vaccines was assessable in the children in the
safety population (n = 204). The incidence rates of AE
were estimated as the case number (n) and proportion
(%) and were compared using the chi-square or Fisher’s
exact test to determine whether there was a difference
between the treatment groups. All statistical analyses
were performed using SAS version 9.2 (SAS Institute
Inc., Cary, NC, USA).
Results
Study population
This study enrolled 205 participants across 10 centers:
103 participants were randomized to KD-287 and 102 to
JEV-GCC, 188 (91.7%; PP population) of whom (93/103
[90.3%] in the test group and 95/102 [93.1%] in the con-
trol group) completed the study up to 6 months afterFigure 1 Analysis populations and excluded subjects.the third vaccination (Figure 1). Seventeen (8.3%) children
were dropped because of eligibility criteria violations
(n = 3; other vaccination 2 weeks before enrollment [n = 1]
and underlying chronic diseases [n = 2]), follow-up loss
(n = 2), withdrawal of consent (n = 3), and protocol viola-
tion before the third vaccination (n = 9; prohibited drug
use [n = 1], visit window deviation [n = 6], over dose [n = 1],
and violation of third vaccination criteria [neurologic SAE;
n = 1]). All participants who decided not to continue with
the study withdrew their consent for personal reasons. All
of the randomized participants (n = 205, 100%; ITT popu-
lation) except one, who voluntarily withdrew before the
first vaccination, were included in the safety population
(n = 204, 99.5%).
Adverse events after vaccination
The overall rates of solicited AEs for KD-287 and JEV-
GCC, which are the proportions of subject having at
least one AE after any vaccination, were 85.3% (87/102)
and 75.5% (77/102), respectively (p = 0.050, Table 1).
Most AEs were mild to moderate in both groups (75/87
[86.2%], KD-287; 67/77 [87.0%], JEV-GCC). The solicited
AE rates associated with the first, second, and third in-
jections of KD-287 were 63.7% (65/102), 44.1% (45/102),
and 46.0% (46/100), respectively, whereas the corre-
sponding rates for JEV-GCC were 52.9% (54/102), 45.0%
(45/100), and 52.1% (50/96), respectively; there were no
significant differences between the two groups when
compared at each vaccination (p = 0.118, 0.900, and 0.394,
respectively).
Table 1 Solicited adverse events after vaccinations at
each dose in the study subjects (safety population)
Group (n) No. (%) of subjects p-value*
AE no AE
Total KD-287 (102) 87 (85.29) 15 (14.71) 0.050
JEV-GCC (102) 77 (75.49) 25 (24.51)
After 1st Vaccination KD-287 (102) 65 (63.73) 37 (36.27) 0.118
JEV-GCC (102) 54 (52.94) 48 (47.06)
After 2nd Vaccination KD-287 (102) 45 (44.12) 57 (55.88) 0.900
JEV-GCC (100) 45 (45.00) 55 (55.00)
After 3rd Vaccination KD-287 (100) 46 (46.00) 54 (54.00) 0.394
JEV-GCC (96) 50 (52.08) 46 (47.92)
AE, adverse event.
*The p-value was calculated using the chi-square test.
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vaccination in both groups are shown in Table 2. Over-
all, the local tolerability and systemic safety profile of
KD-287 was promising in the study, with no serious
safety concerns identified. The most common AE indi-
cated by participants was crying in mild severity (27/102
[26.5%], KD-287; 20/102 [19.6%], JEV-GCC) after first
vaccination. The frequency of most AEs was similar be-
tween the two groups and most local and systemic
events were mild or moderate in severity. Only the total
incidence of fever after the first vaccination was signifi-
cantly different between the two groups (31/102 [30.4%],
KD-287; 15/102 [14.7%], JEV-GCC, p = 0.012). Among
the fever events after the first vaccination in KD-287
and JEV-GCC groups, 61.3% (19/31) and 66.7% (10/15)
were mild severity, respectively.
In total, 52 SAEs were reported: 23 occurred in 17
children in the KD-287 group and 29 occurred in 23
children in the JEV-GCC group (p = 0.373, Table 3).
These events were regarded as most likely not related to
the vaccine itself except for one event of febrile seizure
in the KD-287 group. No vaccine-related hypersensitivity
or neurological AE was reported.
Immunogenicity
The immunogenicity population comprised 188 partici-
pants: 93 in the KD-287 group and 95 in the JEV-GCC
group. The SCRs and GMTs for each group after vac-
cination in the homologous analysis are shown in
Table 4. Before vaccination, none of the children, except
for one in the JEV-GCC group, had detectable anti-
bodies against JEV.
The immunogenicity assessed by SCRs and GMTs at
4 weeks after the third injection was excellent in both
vaccines. Only one subject in JEV-GCC group was not
seroconverted to JEV. The GMTs were higher in the
KD-287 group than they were in the JEV-GCC group
after the third vaccination (GMT ratio: 13.79, p < 0.001).Because the lower limit of the 95% CI for the serocon-
version difference (−1.00%) and for the GMT ratio (10.8)
was higher than −10% and 0.5, respectively, we con-
cluded that KD-287 achieved the non-inferiority criteria.
Furthermore, the SCRs after the second vaccination
and before the third vaccination were excellent in both
groups. The GMTs were higher in the KD-287 group
than they were in the JEV-GCC group after the second
vaccination and before the third vaccination (GMT ratio:
5.59 and 20.13, respectively, p < 0.001 in both). The re-
verse cumulative curve of neutralizing antibodies also re-
vealed that immune responses of the KD-287 group were
greater compared to those of the JEV-GCC group after
the second vaccination and before and after the third vac-
cination, respectively (see Additional file 1: Figure S1).
In the heterologous analysis, the SCRs after the third
injection were excellent in both vaccines, so that only
one subject in KD-287 group was not seroconverted (see
Additional file 2: Table S1). The SCRs in the KD-287
group were higher than those in the JEV-GCC group,
both after the second vaccination (94.62% and 54.74%,
respectively) and before the third vaccination (93.55%
and 34.74%, respectively). Against the heterologous strain,
the GMTs were higher in the KD-287 group than they
were in the JEV-GCC group after the second vaccination
and before and after the third vaccination (GMT ratio:
4.05, 5.15, and 4.19, respectively, p < 0.001 in all). The
lower limits of the 95% CI both for the seroconversion dif-
ference (−3.2) and for the GMT ratio (3.2) in the heterol-
ogous analysis also fulfilled the non-inferiority criteria.
Before the third vaccination, children in the JEV-GCC
group showed slightly reduced GMTs compared with
the GMTs after the second vaccination, but satisfactory
GMTs were obtained against both homologous and
heterologous strains (Figure 2). However, the GMTs be-
fore the third vaccination in the KD-287 group were
higher than the GMTs after the second vaccination for
both tested strains. After the third vaccination, the neu-
tralizing antibody titer increased in all children, and the
GMTs in both groups were higher than the respective
GMTs after the second vaccination.
Discussion
We performed a phase III clinical study of a JE-VC pre-
pared with the Beijing-1 strain, KD-287, with the aim of
determining whether its immunogenicity is not inferior
and its safety is comparable to those of the currently
used JE-MB prepared with the Nakayama strain, JEV-
GCC, in Korean children. Statistical non-inferiority of
KD-287 to JEV-GCC was demonstrated in terms of
SCRs and GMTs at 4 weeks after the third vaccination.
Neutralizing antibody titers were significantly higher in the
KD-287 group than in the JEV-GCC group after the second
vaccination and before and after the third vaccination.
Table 2 Incidence of solicited adverse events within 7 days after each vaccination (safety population)













Erythema Mild 9 (8.8) 18 (17.6) 7 (6.9) 14 (14.0) 7 (7.0) 14 (14.6)
Moderate 3 (2.9) 2 (2.0) 5 (4.9) 2 (2.0) 7 (7.0) 6 (6.3)
Severe 1 (1.0) 0 (0) 0 (0) 0 (0) 1 (1.0) 0 (0)
Pain Mild 14 (13.7) 10 (9.8) 3 (2.9) 5 (5.0) 18 (18.0) 11 (11.5)
Moderate 2 (2.0) 2 (2.0) 2 (2.0) 1 (1.0) 2 (2.0) 3 (3.1)
Severe 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (1.0)
Swelling Mild 3 (2.9) 7 (6.9) 6 (5.9) 7 (7.0) 5 (5.0) 11 (11.5)
Moderate 2 (2.0) 1 (1.0) 2 (2.0) 1 (1.0) 1 (1.0) 2 (2.1)
Severe 1 (1.0) 0 (0) 0 (0) 0 (0) 1 (1.0) 0 (0)
Fever Mild 19 (18.6) 10 (9.8) 13 (12.7) 12 (12.0) 13 (13.0) 14 (14.6)
Moderate 8 (7.8) 4 (3.9) 2 (2.0) 4 (4.0) 1 (1.0) 3 (3.1)
Severe 4 (3.9) 1 (1.0) 2 (2.0) 3 (3.0) 0 (0) 1 (1.0)
Crying Mild 27 (26.5) 20 (19.6) 15 (14.7) 6 (6.0) 14 (14.0) 14 (14.6)
Moderate 5 (4.9) 4 (3.9) 3 (2.9) 6 (6.0) 2 (2.0) 3 (3.1)
Severe 2 (2.0) 0 (0) 0 (0) 1 (1.0) 0 (0) 1 (1.0)
Irritability Mild 12 (11.8) 11 (10.8) 5 (4.9) 6 (6.0) 13 (13.0) 4 (4.2)
Moderate 1 (1.0) 4 (3.9) 2 (2.0) 5 (5.0) 0 (0) 6 (6.3)
Severe 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Vomiting Mild 8 (7.8) 11 (10.8) 4 (3.9) 3 (3.0) 1 (1.0) 4 (4.2)
Moderate 2 (2.0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Severe 1 (1.0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Diarrhea Mild 17 (16.7) 11 (10.8) 3 (2.9) 5 (5.0) 3 (3.0) 4 (4.2)
Moderate 4 (3.9) 1 (1.0) 0 (0) 2 (2.0) 0 (0) 2 (2.1)
Severe 0 (0) 1 (1.0) 0 (0) 0 (0) 1 (1.0) 1 (1.0)
Decreased appetite Mild 10 (9.8) 13 (12.7) 5 (4.9) 8 (8.0) 6 (6.0) 8 (8.3)
Moderate 2 (2.0) 0 (0) 0 (0) 1 (1.0) 1 (1.0) 0 (0)
Severe 2 (2.0) 0 (0) 1 (1.0) 0 (0) 0 (0) 1 (1.0)
Somnolence Mild 9 (8.8) 12 (11.8) 8 (7.8) 7 (7.0) 14 (14.0) 17 (17.7)
Moderate 0 (0) 1 (1.0) 0 (0) 1 (1.0) 0 (0) 0 (0)
Severe 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
*Number of subjects reporting the specific characteristic.
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systemic tolerability profiles were comparable to those of
JEV-GCC, except for a higher incidence of fever after the
first vaccination. The frequency of AEs was similar be-
tween the two groups, and vaccine-related AEs were
generally mild. There was no notable SAE, including
neurologic symptoms, in the two vaccine groups.
JEV is regarded as one of the most serious viral causes
of encephalitis, with a mortality of 30% and a high rate
of neurologic sequelae in survivors [1]. Because no anti-
viral treatment is available, prevention of infection is
particularly important. Routine immunization programs
against JE are generally recommended for populationsresiding in endemic areas. In developed, non-endemic
countries, vaccinations are recommended for travelers to
endemic regions [2,16].
The Nakayama strain of the JEV was isolated from the
cerebral spinal fluid of a patient in 1935 and was main-
tained by continuous mouse-brain passage. The Nakayama
strain JE-MB has been the dominant vaccine throughout
Asia, with the exception of the Beijing strain product,
which was produced in Japan from 1988 to 2005 [16,17].
The residual mouse brain neural tissue content of the vac-
cine has raised concerns regarding safety and the possibil-
ity of vaccine-related neurological adverse events [18,19].
Furthermore, the manufacture of the vaccine is associated




No. of subjects, n (%) p-value*
KD-287 (n = 102) JEV-GCC (n = 102)
Total 17 (16.67) 23 (22.55) 0.373
Febrile seizure 1 (0.98) - 1.000
Otitis Media 1 (0.98) 1 (0.98) 1.000
Pharyngitis 2 (1.96) 1 (0.98) 1.000
Laryngitis 1 (0.98) - 1.000
Bronchitis 4 (3.92) 4 (3.92) 1.000
Pneumonia 5 (4.90) 13 (12.75) 0.127
Influenza - 1 (0.98) 1.000
Gastroenteritis 1 (0.98) 3 (2.94) 0.369
Others† 2 (1.96) - 0.498
*The p-value was calculated using the chi-square or Fisher’s exact test.
†Others included a case of vaccine overdose and a case of accessory skin tag.
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cost, and ethical issues related to the use of animals. At
present, JE-VCs, live-attenuated virus vaccines, and re-
combinant chimeric virus vaccines (JE-CVs) are available
as second-generation JE vaccine alternatives to JE-MB [4].
Sugawara et al. found that Vero cells show a high sus-
ceptibility to JEV and that the virus shows good prolifer-
ation in cultured cells [20]. They also confirmed that the
viral antigens derived from mouse brain and Vero cells have
similar physicochemical and immunological characteristicsTable 4 Seroconversion rates and geometric mean titers after v
population, homologous response)
Time point Value KD-2
SCR Seropositive at baseline n (%) 0 (0.
95% CI
After 2nd dose n (%) 93 (1
95% CI
Before 3rd dose n (%) 93 (1
95% CI
After 3rd dose n (%) 93 (1
95% CI (100
GMT Before Vaccination log10n 5
95% CI (5, 6
After 2nd dose log10n 601
95% CI (509
Before 3rd dose log10n 917
95% CI (757
After 3rd dose log10n 1334
95% CI (114
SCR, seroconversion rate; GMT, geometric mean titer; CI, confidence interval.
*Difference is KD-287 minus JEV-GCC for SCR and ratio is KD-287 divided by JEV-GC
†The p-value was calculated using the t-test for GMT; p < 0.001 in all.and that Vero cell-derived antigens could be used as a
vaccine. The IC51 vaccine (IXIARO®) is a formalin-
inactivated JE-VC prepared with the whole-virus SA 14-
14-2 strain that was developed by Intercell Biomedical
(Livingston, UK) [20]. IC51 has been licensed and indi-
cated for prevention of JE in individuals aged ≥2 months
in Europe and the United States. Recently, a JE-VC simi-
lar to IC51 became available in India and is manufactured
by Biological E using technology transferred from Inter-
cell [21,22]. In Japan, freeze-dried, inactivated JE-VCs
prepared with the Beijing-1 strain are distributed by two
manufacturers: Biken (JEBIK V®; BK-VJE) and the Chemo-
Sero-Therapeutic Research Institute (ENCEVAC®; KD-
287). These two JE-VCs were approved in Japan as a
substitute for JE-MB in 2009 and 2011, respectively, and
they are indicated for prevention of JE in individuals
aged ≥6 months [4,10,23]. However, in South Korea,
only JE-MBs locally produced using the Nakayama strain
and a live-attenuated virus vaccine prepared with the SA
14-14-2 strain have been used for immunization of chil-
dren [6,7].
Although several JE vaccines are in use today, only the
formalin-inactivated JE vaccine has been evaluated in
placebo-controlled trials [16,24]. After the efficacy of
purified JE-MB vaccines was demonstrated in these
studies, placebo-controlled JE vaccine efficacy trial was
considered unethical. In addition, a comparative trial be-
tween a licensed vaccine and a new vaccine using the
endpoint of prevention of clinical illness would requireaccination compared to before vaccination (per-protocol
87 (n = 93) JEV-GCC (n = 95) *Difference/Ratio
0) 1 (1.0)
00.0) 93 (97.9) 2.1
(−0.78, 4.99)
00.0) 90 (94.7) 5.3
(0.77, 9.75)
00.0) 94 (98.9) 1.1




, 709) (84, 137) (4.2, 7.5)
45 20.1†
, 1110) (36, 56) (15.2, 26.7)
7 967 13.8†
55, 15551) (798, 1172) (10.8, 17.6)
C for GMT.
Figure 2 Changes of mean neutralizing antibody titers before and after vaccination. Satisfactory geometric mean titers (GMTs) were
obtained after the second vaccination and before and after the third vaccinations in both vaccine groups, in both homologous and heterologous
analyses. The GMTs before the third vaccination in the KD-287 group were higher than those after the second vaccination for both tested strains.
After the third vaccination, the neutralizing antibody titer increased in all children, and the GMTs in both groups were higher than the respective
GMTs after the second vaccination.
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determine a vaccine-induced immunological marker that
may be used as a surrogate to indicate protection from
disease [14]. It has been established that neutralizing
antibodies provide the best evidence of protective im-
munity, and functional assays of neutralization show a
correlation with protection. A linear titer-protection rela-
tionship exists, and data from efficacy trials corroborate
the role of neutralizing antibodies in protection [14,25].
The immunogenicity and safety of a 2-dose primary
series of IC51 (IXIARO®) has been demonstrated for
adults in two large company-coordinated, non-inferiority
randomized controlled trials (RCTs) [8,9]. In addition to
having a favorable safety and tolerability profile, the SCR
induced by two IC51 (SA 14-14-2 strain) doses (98%)
was demonstrated to be non-inferior to the SCR induced
by three doses of a JE-MB (Nakayama strain) (95%). Fur-
thermore, the GMT after IC51 vaccination was 2-fold
higher than that after JE-MB vaccination, although
GMTs were evaluated against the homologous strain for
IC51 and the heterologous strain for JE-MB [8]. The im-
munogenicity and safety of IC51 were then evaluated in
healthy children between 1 and 3 years of age in a phase II
study [11]. At 56 days after vaccination, the SCR of the
3 μg and 6 μg IC51 groups and the JE-MB (Nakayama
strain) group were 95.7%, 95.2%, and 90.9%, respectively
(p > 0.05). There was no apparent difference in the safety
profile between the vaccines. Recently, it was shown that a
single dose of IC51 effectively boosted immunity in adults
primed with a JE-VC [26,27] or a JE-MB [15,28].
Another JE-VC, BK-VJE (Beijing-1 strain) was recently
evaluated for immunogenicity and safety in Japanesechildren aged 6–90 months [10,23]. BK-VJE at one half of
the potency of a JE-MB (Beijing-1 strain) was sufficient to
induce the comparable neutralizing antibody titer to JE-
MB at full potency, and there was no withdrawal of sub-
jects as a result of vaccine-related adverse events.
In addition, two RCTs with KD-287 were conducted in
healthy children aged 6–90 months in Japan [12]. The
KD-287 was in liquid form in one study and in freeze-
dried form in the other study. Both forms of the test vac-
cine and control vaccine (liquid form, JE-MB prepared
with the Beijing-1 strain) were injected twice at a 1–4
week interval, and the third dose was injected 1–15
months later. After the third injection, the SCRs in the
KD-287 and the control vaccine groups were 100% in both
studies. The GMTs after the second and third injection
were both significantly higher in the KD-287 group than
those in the control vaccine group in both studies. Al-
though there were no important safety issues in both stud-
ies, low-grade fever was more prevalent in the KD-287
group than in the control vaccine group. In this study, we
performed a double-blind phase III RCT to assess the
safety and immunogenicity of KD-287 in Korean healthy
children aged 12–23 months. The two vaccines were dif-
ferent with regard to the method used for JEV propagation
(Vero cells vs. mouse brain) and were also different with
regard to the JEV strain included (Beijing-1 vs. Nakayama).
All JEV strains belong to a single serotype and are
classified in five genotypes. All currently available JE vac-
cines are prepared from genotype III strains, and the
JEV strains prevalent in South Korea are mostly from
genotype I, and more recently genotype V [29]. However,
the genotype of JEV strain in a JE vaccine may not affect
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ous JE vaccine immunogenicity studies, only the hom-
ologous virus strain was used in PRNT assays for each
vaccine [8,11,12,23,26-28]. In the studies where the virus
strains of the test and control vaccines were heterol-
ogous, the PRNT assay favored the vaccine homologous
to the target strain [15,30-32]. The JE vaccine prepared
with the Beijing-1 strain induced higher levels of neu-
tralizing antibodies against heterologous JE strains than
the JE vaccine prepared with the Nakayama strain. How-
ever, JE vaccines prepared using either the Beijing-1 or
Nakayama strains can induce effective protective im-
munity against heterologous JEV strains. We tested all
serum samples against both of the vaccine strains in-
cluded in JE-MB and JE-VC (Nakayama and Beijing-1)
as previously suggested [15].
JE-VC and JE-MB are thought to have similar proper-
ties; however, some differences exist in the vaccine
manufacturing processes. For instance, the inactivation
and purification conditions for JE-VC are milder than
those used for JE-MB. Electron microscopy showed that
JE-MB contains virions with a somewhat smooth sur-
face, whereas the surface of JE-VC virus particles is more
similar to that of the native virus. Thus, the conform-
ation of the E protein on the virus surface may be better
conserved in JE-VC, which may be important for the su-
perior immunogenicity of JE-VC [10].
In this study, the SCRs after a three-dose injection of
the KD-287 were excellent in both homologous and
heterologous analyses. Compared with the licensed con-
trol vaccine, KD-287 fulfilled the non-inferiority criteria.
Furthermore, the GMTs at three test points after vaccin-
ation of KD-287 were significantly higher than those of
the control vaccine in both homologous and heterol-
ogous analyses. These results agree with the findings of
previous RCTs comparing JE-VC with JE-MB [8,10,12,23].
Non-inferiority of KD-287 to the control vaccine with re-
gard to the GMT ratio was also confirmed in this study.
Interestingly, the GMTs before the third vaccination were
higher than those after the second vaccination in the KD-
287 group. Because there was an 11-month interval be-
tween the second and third samplings, the GMTs were
generally expected to decrease temporally. It is possible
that we did not select the time point with peak neutraliz-
ing antibody production after the second JE vaccination,
especially in the KD-287 group. Neutralizing antibody
production may continue beyond 4 weeks after the second
injection; thus, the peak GMTs after the second vaccin-
ation may actually be higher than the values we observed
in the KD-287 group. Previous studies showed approxi-
mately two-fold higher GMTs for JE-VC than for JE-MB
[8,10,23], but the GMTs after three doses of JE-VC pre-
pared with Beijing-1 strain JEV were approximately 14-
fold higher than those of JE-MB prepared with Nakayamastrain JEV in this study. We speculate that the Beijing-1
strain of JEV may be more immunogenic than the
Nakayama strain of JEV in healthy Korean children.
The safety and tolerability with the KD-287 were excel-
lent in this study. As shown in Table 1, the rate of solicited
AEs reported after each dose was not significantly differ-
ent between the two vaccines, although the total incidence
of solicited AEs in the KD-287 group was higher than that
in the control vaccine group (borderline statistical sig-
nificance [p = 0.050]). Furthermore, severe AEs were in-
frequent in both vaccine groups (12/102 [13.8%] in the
KD-287 group, 10/102 [13.0%] in the JEV-GCC group,
p > 0.05). The rates of all solicited AEs within 7 days after
each vaccination were also not significantly different be-
tween the vaccine groups, except the higher incidence of
mild fever events after the first injection of KD-287 than
that of JEV-GCC. As an increased incidence of mild fever
for freeze-dried, but not liquid, KD-287 was also identified
in a previous study [12], further efforts to identify and
eliminate the cause of fever are necessary for KD-287.
The rates of all SAEs also did not differ between the
vaccine groups. Only one febrile seizure event in the
KD-287 group may have been associated with vaccin-
ation. Although there was remarkably high incidence of
SAEs in both groups, it was possibly due to the high
medical attention of parents of study subjects and spe-
cific situation in Korean healthcare system convenient to
be hospitalized. There were no serious neurologic ad-
verse reactions in the study and almost all children com-
pleted the three-dose regimen. The three-dose schedule
of KD-287 will most likely have an acceptable tolerability
with a low frequency of vaccine-related adverse reactions
in children aged 12–23 months.
This study is limited by differences between the two
vaccines in the method of JEV propagation (Vero cells vs.
mouse brain) and in the JEV strains included (Beijing-1 vs.
Nakayama). We could not measure the actual effect of the
vaccines against JE in the children.
Conclusions
In this study, we confirmed that KD-287, the JE-VC pre-
pared with the Beijing-1 strain, showed a comparable
safety profile with and a higher immunogenicity than the
JE-MB prepared with the Nakayama strain. Furthermore,
a positive booster effect was also recognized after a third
dose of either vaccine. In conclusion, KD-287 could be
useful as a second-generation vaccine and substitute for
the currently used JE-MB vaccine in South Korea.
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